Free diabetic retinopathy risk calculator from ADA
Encourage your patients to use the clinically validated RetinaRisk calculator to learn their risk of developing diabetic retinopathy, better understand the factors affecting their risk, and ways to prevent vision complications. View the calculator.
Eli Lilly's biosimilar insulin wins FDA nod
Eli Lilly and Co.'s Rezvoglar has received FDA approval as the second biosimilar version of Lantus, or insulin glargine, for improving glycemic control in children and adults with diabetes. The biosimilar can be used as substitute for Lantus, but it requires its own prescription, as the products are not deemed interchangeable.
Assessment of Hypothetical Out-of-Pocket Costs of Guideline-Recommended Medications for the Treatment of Older Adults With Multiple Chronic Conditions, 2009 and 2019
Tianna Zhou, BS; Patrick Liu, MD; Sanket S. Dhruva, MD, MHS; et al.
From Denise: note that the ADA guideline used was from 2018, before the strengthening of initial treatment recommendations for GLP-1RA and SGLT2i for heart and kidney conditions regardless of A1C